Several other analysts have also issued reports on the company. Goldman Sachs Group initiated coverage on Frequency Therapeutics in a report on Monday, October 28th. They set a buy rating and a $30.00 price target for the company. JPMorgan Chase & Co. initiated coverage on Frequency Therapeutics in a report on Monday, October 28th. They set an overweight rating and a $25.00 price target for the company. Finally, Cowen assumed coverage on Frequency Therapeutics in a report on Monday, October 28th. They set an outperform rating for the company.
NASDAQ:FREQ traded up $0.76 during mid-day trading on Thursday, hitting $16.50. 137,000 shares of the company traded hands, compared to its average volume of 119,116. Frequency Therapeutics has a one year low of $11.17 and a one year high of $17.44.
Frequency Therapeutics Company Profile
Frequency Therapeutics, Inc, a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue.
Featured Article: Market Indexes
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Frequency Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Frequency Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.